Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY2416964 |
Synonyms | |
Therapy Description |
BAY2416964 binds to and inhibits aryl hydrocarbon receptor (AhR) signaling, which may restore anti-tumor immune response in the tumor microenvironment (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2416964 | BAY-2416964|BAY 2416964 | BAY2416964 binds to and inhibits aryl hydrocarbon receptor (AhR) signaling, which may restore anti-tumor immune response in the tumor microenvironment (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04999202 | Phase I | BAY2416964 + Pembrolizumab BAY2416964 | A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults | Active, not recruiting | USA | ITA | GBR | 1 |
NCT04069026 | Phase I | BAY2416964 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | Completed | USA | GBR | ESP | DEU | CAN | 0 |